Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroaki Ohi is active.

Publication


Featured researches published by Hiroaki Ohi.


Archives of Biochemistry and Biophysics | 1989

Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers.

Masayuki Komori; Kanako Nishio; Tomomichi Fujitani; Hiroaki Ohi; Mitsukazu Kitada; Satoaki Mima; Koshiro Itahashi; Tetsuya Kamataki

From a human fetal liver cDNA library, a new cDNA clone (lambda HFL10) was isolated using an antiserum to P450 HFLa, which has been isolated from livers of human fetuses. Cytochrome P450 cDNAs, namely lambda hPA6, lamda hP2-1, and lambda hPD4 which were highly homologous to cDNA clones, pHY13, Hp1-1, and phP450j, respectively, were also isolated from the cDNA library of human adult livers. Using these cDNA clones as probes together with Lambda HFL10, Northern blot analysis was conducted to determine whether all of these cytochromes were expressed in human fetal livers. The results clearly showed that only P450 HFL10 mRNA was detected in human fetal livers. This result supports the allegation that there is a much more limited number of forms of cytochrome P450 in human fetal livers than in adult livers.


Mutation Research | 1989

Mutagenic activation of aflatoxin B1 by P-450 HFLa in human fetal livers.

Mitsukazu Kitada; Masaki Taneda; Hiroaki Ohi; Masayuki Komori; Koshiro Itahashi; Minako Nagao; Tetsuya Kamataki

The genotoxic and mutagenic activation of promutagens by human fetal livers was measured by the induction of umu gene expression in Salmonella typhimurium TA1535/pSk1002. Liver homogenates of human fetuses were the most active for the mutagenic activation of aflatoxin B1 (AFB1), followed by 2-amino-3-methylimidazo(4,5-f)quinoline (IQ), and to a lesser extent by 2-amino-6-methyldipyrido(1,2-a:3,2-d)imidazole (Glu-P-1). The amounts of P-450 HFLa immunochemically determined in human fetal livers correlated highly with the induction of umu gene expression by AFB1 (r = 0.98, n = 5). P-450 HFLa catalyzed the mutagenic activation of AFB1 in a reconstituted system: cytochrome b5 markedly stimulated the activation. Anti-P-450 HFLa antibodies inhibited the mutagenic activation of AFB1 in a dose-dependent manner. These results strongly support the idea that P-450 HFLa is responsible for the mutagenic activation of AFB1 in human fetal livers.


Biochimica et Biophysica Acta | 1989

Purification of cytochrome P-450 from polychlorinated biphenyl-treated crab-eating monkeys: high homology to a form of human cytochrome P-450

Kazuhide Ohta; Mitsukazu Kitada; Takanori Hashizume; Masayuki Komori; Hiroaki Ohi; Tetsuya Kamataki

Cytochrome P-450, designated as P-450-MK2, was purified to an electrophoretic homogeneity from polychlorinated biphenyl (PCB)-treated female crab-eating monkeys. P-450-MK2 catalyzed nifedipine and nilvadipine oxidations, at a rate comparable to human P-450-HM1. The N-terminal amino acid sequence of P-450-MK2 was highly homologous to those of P-450-HM1 and NF 25. The antibodies to P-450-HM1 recognized P-450-MK2 and effectively inhibited the activity of testosterone 6 beta-hydroxylase in monkey liver microsomes. These results suggest that a form of cytochrome P-450 corresponding to human P-450-HM1 or P-450NF which belongs to the P450 III gene family is also present in liver microsomes of crab-eating monkeys.


Mutation Research | 1989

Interspecies homology of cytochrome P-450: toxicological significance of cytochrome P-450 cross-reactive with anti-rat P-448-H antibodies in liver microsomes from dogs, monkeys and humans

Kazuhide Ohta; Mitsukazu Kitada; Hiroaki Ohi; Masayuki Komori; Kazuo Nagashima; Noriyuki Sato; Kozo Muroya; Takao Kodama; Minako Nagao; Tetsuya Kamataki

The mutagenic activation of various promutagens by liver microsomes from dogs, monkeys and humans was investigated. Dog liver microsomes efficiently catalyzed the mutagenic activation of Trp-P-2 and Glu-P-1 followed by IQ and AAF. Monkey liver microsomes were most active in the activation of IQ followed by Glu-P-1, AAF and Trp-P-2. Although there were remarkable individual differences, human liver microsomes were found to be most active in the mutagenic activation of IQ followed by Trp-P-2, Glu-P-1 and AAF. Antibodies against rat P-448-H inhibited the mutagenic activation of Glu-P-1, Trp-P-2 and IQ in rat and dog liver microsomes, and Glu-P-1 and Trp-P-2 in monkey liver microsomes. The activation of Glu-P-1 and IQ in human liver microsomes was also strongly inhibited by anti-P-448-H antibodies. The amounts of cytochrome P-450 cross-reactive with anti-P-448-H antibodies in human liver microsomes highly correlated with the capacity to activate Glu-P-1, Trp-P-2 and IQ but not AAF.


Mutation Research | 1992

Toxicological sifnificance of dog liver cytochrome P-450: examination with the enzyme expressed in Saccharomycees cerevisiae using recombinant expression plasmid

Hiroko Fukuta; Hiroaki Ohi; Taisuke Uchida; Masayuki Komori; Mitsukazu Kitada; Tetsuya Kamataki

A complementary DNA (cDNA) coding for a form of beagle dog cytochrome P-450 (Dah1), which is the orthologue to the CYP1A1 cDNA of rat, mouse and human, was inserted between the alcohol dehydrogenase (ADH) promoter and terminator regions of the yeast expression vector pAAH5. On introduction of the resulting recombinant plasmid pDC-1, Saccharomyces cerevisiae strain AH22 cells synthesized up to 1.5 x 10(5) molecules per cell of cytochrome P-450 protein (P-450(Dah1)). The carbon monoxide-bound reduced form of P-450(Dah1) showed an absorption peak at 447 nm and specific content of P-450(Dah1) was about 0.1 nmole P-450 per mg of microsomal protein. P-450(Dah1) cross-reacted with antibodies to rat P-448-H (CYP1A2) and dog P-450-D2 (CYP1A2). P-450(Dah1) activated 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ) and 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ) most efficiently in the umu test and exhibited a high activity of aryl hydrocarbon hydroxylase toward benzo[a]pyrene.


Biochemical Pharmacology | 1989

Effects of serum testosterone level with buserelin on the activities of drug and testosterone hydroxylase and on the content of a male-specific form of cytochrome P-450 in male rats

Hiroaki Ohi; Mlyuki Iwasaki; Masayuki Komori; Toshiaki Miura; Mitsukazu Kitada; Shoryo Hayashi; Tetsuya Kamataki

The effects of administration of buserelin, a synthetic agonist of lutenizing hormone-releasing hormone (LH-RH), on the content of P-450-male, a male specific form of cytochrome P-450, and the activities of drug and testosterone hydroxylases were examined in liver microsomes of male rats. Administration of buserelin resulted in a decrease in the serum level of testosterone in a dose-dependent manner. Similar decreases were seen in the activities of aminopyrine N-demethylase, 7-propoxycoumarin O-depropylase and testosterone 2 alpha- and 16 alpha-hydroxylases, but not in the activity of aniline p-hydroxylase. Thus, correlations were observed between the serum level of testosterone and the activities of drug and testosterone hydroxylases except for aniline p-hydroxylase. These results indicate that the drug and testosterone hydroxylases are affected sensitively and sequentially by the changes in the testosterone levels in the body.


Journal of Biochemistry | 1989

Molecular Cloning and Sequence Analysis of cDNA Containing the Entire Coding Region for Human Fetal Liver Cytochrome P-450

Masayuki Komori; Kanako Nishio; Hiroaki Ohi; Mitsukazu Kitada; Tetsuya Kamataki


Journal of Biochemistry | 1988

Cytochrome P-450 in Human Liver Microsomes: High-Performance Liquid Chromatographic Isolation of Three Forms and Their Characterization

Masayuki Komori; Takanori Hashizume; Hiroaki Ohi; Toshiaki Miura; Mitsukazu Kitada; Kazuo Nagashima; Tetsuya Kamataki


Research communications in chemical pathology and pharmacology | 1989

Form-specific degradation of cytochrome P-450 by lipid peroxidation in rat liver microsomes

Mitsukazu Kitada; Masayuki Komori; Hiroaki Ohi; Imaoka S; Funae Y; Tetsuya Kamataki


Journal of Antimicrobial Chemotherapy | 1989

Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics

Toshiaki Miura; Miyuki Iwasaki; Masayuki Komori; Hiroaki Ohi; Mitsukazu Kitada; Hideki Mitsui; Tetsuya Kamataki

Collaboration


Dive into the Hiroaki Ohi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Toshiaki Miura

Hokkaido College of Pharmacy

View shared research outputs
Top Co-Authors

Avatar

Koshiro Itahashi

Kawasaki Steel Corporation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge